Circulating free DNA in the era of precision oncology: Pre‐ and post‐analytical concerns
Tóm tắt
Tài liệu tham khảo
10.1053/j.seminhematol.2010.07.001
10.1200/JCO.2003.10.038
10.1056/NEJMoa044238
10.1200/JCO.2010.33.4235
10.1056/NEJMp1500523
10.1038/nm0313-249
10.3389/fgene.2016.00060
National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease, 2011, Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease
10.1371/journal.pone.0161012
Jahr S., 2001, DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells, Cancer Res, 61, 1659
Zhivotosky B., 2001, Assessment of apoptosis and necrosis by DNA fragmentation and morphological criteria, 10.1002/0471143030.cb1803s12
10.1016/S0009-8981(01)00665-9
10.18632/oncotarget.6874
10.1371/journal.pone.0108247
10.1097/JTO.0b013e3182307f98
10.1373/clinchem.2016.257469
10.1038/srep31985
10.1158/1078-0432.CCR-15-2470
10.1038/nm.1789
Wu Y.L., 2016, Liquid biopsy: specification with precision, J Evid Based Med, 16, 193
10.1111/bju.13586
10.1007/s00428-016-2004-z
List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools).http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm. Updated October 28 2016. Accessed December 1 2016.
10.1186/s40880-016-0092-4
10.1038/nrc3066
10.3390/ijms140918925
10.1634/theoncologist.2016-0082
10.1038/nm.3519
10.1016/j.tig.2015.02.001
10.1158/2159-8290.CD-15-0344
10.1371/journal.pcbi.1004731
10.1007/978-94-017-7484-0
10.2196/resprot.6024
10.1186/s13058-016-0696-2
10.1158/2159-8290.CD-15-1283
10.1038/nature08658
10.1530/ERC-15-0369
10.1073/pnas.1519286113
10.1373/clinchem.2015.253609
10.1016/j.ebiom.2015.08.015
10.1371/journal.pgen.1006162
10.1073/pnas.1500076112
10.1073/pnas.1501321112
10.1371/journal.pone.0023418
10.1182/blood-2013-02-485771
10.1093/clinchem/48.10.1647
10.1101/gr.192294.115
10.1016/j.cell.2015.11.050
10.1126/sciadv.1500734
10.1021/nl3039162
10.1517/14712598.2012.673577
Korabecna M., 2011, Circulating Nucleic Acids in Plasma and Serum: Proceedings of the 6th International Conference on Circulating Nucleic Acids in Plasma and Serum Held on 9–11 November 2009 in Hong Kong, 195
10.1373/clinchem.2003.026013
10.1016/j.clinbiochem.2016.03.012
10.1371/journal.pone.0025202
10.1016/j.cca.2015.08.028
10.1016/j.dib.2015.12.009
10.1515/cclm-2014-1161
10.3349/ymj.2012.53.1.132
10.1016/j.cca.2011.07.011
10.1007/978-3-319-42044-8_33
10.1371/journal.pone.0077963
10.1016/j.jchromb.2006.04.026
Ford A., 2015, Next‐generation liquid biopsy: tumor monitoring from droplet volumes of blood, J Cancer Prev Curr Res, 3, 00064
10.1016/j.cca.2009.02.018
Parpart‐Li ST Bartlett B Popoli M et al.The effect of preservative and temperature on the analysis of circulating tumor DNA[published online ahead of print November 8 2016].Clin Cancer Res. doi:10.1158/1078‐0432.CCR‐16‐1691.
10.1371/journal.pone.0150197
10.1016/j.biomaterials.2016.06.003
10.1200/JCO.2006.05.9493
10.1371/journal.pone.0087838
10.1136/jclinpath-2014-202404
ISO/TC 212ISO 15189:2012.Medical Laboratories—Requirements for Quality and Competence.2012
ISO/CASCOISO/IEC 17025:2005.General Requirements for the Competence of Testing and Calibration Laboratories.2005
10.1016/j.jcv.2012.11.013
10.1038/ejhg.2010.101
10.1038/nbt.2696
10.1038/nm.3511
10.1007/s00216-014-7835-3
Duan H., 2015, Comparison of EGFR mutation status between plasma and tumor tissue in non‐small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation status, Int J Clin Exp Pathol, 8, 13136
10.1038/srep06269
Chae YK Davis AA Carneiro BA.Concordance between genomic alterations assessed by next‐generation sequencing in tumor tissue or circulating cell‐free DNA[published online ahead of print August 30 2016].Oncotarget. doi:10.18632/oncotarget.11692.
10.1056/NEJMsb1607705